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Introduction
The Polycomb Group (PcG) and trithorax Group (trxG) pro-
teins are epigenetic regulators.1 PcG proteins are required to
epigenetically silence their target genes, whereas trxG pro-
teins maintain transcriptional activation.2 Additional sex comb-
like 1 (ASXL1) belongs to the Enhancer of trithorax and
Polycomb genes, which are responsible for maintaining acti-
vation and silencing of PcG and trxG proteins.2 ASXL1 is a
highly conserved gene consisting of an N-terminal ASX
homology domain and a C-terminal plant homeodomain fin-
ger region (PHD).3 Somatic mutations in the ASXL1 gene have
been described in various types of myeloid malignances: 11%
myelodysplastic syndrome (MDS),4 8% myeloproliferative
neoplasia,5 49% of chronic myelomonocytic leukemia,6
10.8% of de novo acute myeloid leukemia (AML)7 and 23% of
post-MDS AML.8 Mutations were all found in exon 12 of the
gene and cause truncation of the protein with loss of the PHD
domain.4-8
The prevalence and prognostic value of ASXL1 mutations
(ASXL1mut) in AML have not been extensively described.7
However, thorough analyses of novel markers in independent
clinical trials are warranted before implementation of these
markers in treatment decision-making can be considered. In
this study, we determined the ASXL1 mutations in a cohort
of 882 cases of AML. We investigated their distribution in
relationship with cytogenetic and molecular risk categories,
and we evaluated the impact of these mutations on survival
and relapse.
Design and Methods
Bone marrow aspirates or peripheral blood samples of cohorts of
patients with various hematologic malignancies were collected after
obtaining written informed consent in accordance with the
Declaration of Helsinki. This research has been reviewed and
approved by the Erasmus University Medical Center Medical Ethical
Review Committee (MEC-2004-030). AML patients were treated
according to the HOVON (Dutch-Belgian Hematology-Oncology Co-
operative group) protocols HO04, HO04A, HO29, HO42, HO42A
and HO43 (http://www.hovon.nl).9-12
Mutation detection in FLT3 (internal tandem duplications (ITD) or
tyrosine kinase domain mutations (TKD)), NPM1, N-RAS, IDH1 and
IDH2, as well as EVI1 overexpression were performed as described
previously.13-17
ASXL1 mutations in AML were determined by cDNA amplifica-
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Somatic mutations in the additional sex comb-like 1 (ASXL1)
gene have been described in various types of myeloid malig-
nancies, including acute myeloid leukemia. Analysis of novel
markers, such as ASXL1 mutations, in independent clinical tri-
als is indispensable before considering them for clinical deci-
sion-making. We analyzed 882 well-characterized acute
myeloid leukemia cases to determine the prevalence and prog-
nostic impact of ASXL1 exon12 mutations. Truncating ASXL1
mutations were present in 46 cases (5.3%). ASXL1 mutations
were inversely associated with FLT3 internal tandem duplica-
tions and mutually exclusive with NPM1 mutations. ASXL1
mutations were an unfavorable prognostic factor as regards
survival (median overall survival 15.9 months vs. 22.3 months;
P=0.019), with a significantly lower complete response rate
(61% vs. 79.6%; P=0.004). In multivariate analyses, ASXL1
mutations were independently associated with inferior poor
overall survival (HR 1.52, P=0.032). In conclusion, ASXL1
mutations are common mutations in acute myeloid leukemia
and indicate a poor therapy outcome.
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ABSTRACT
tions using Fw-ASXL1-Ex12 5’-CCACCCTGGGTGGTTAAAG-3’
and Rev-ASXL1-Ex12 5’-TCGCTGTAGATCTGACGTAC-3’. By
this approach 83% of all known exon 12 ASXL1 mutations are
identified (range P575 to R687 of ASXL1).7
All PCR reactions were carried out at an annealing temperature
of 60°C in the presence of 25mM dNTP, 15 pmol primers, 2mM
MgCl2, Taq polymerase and 1 x buffer (Invitrogen Life
Technologies, Breda, The Netherlands). Cycling conditions were
as follows: 1 cycle 5' at 94°C, 35 cycles 1' at 94°C, 1' at 60°C, 1' at
72°C, and 1 cycle 7' at 72°C. All ASXL1 RT-PCR products were
subjected to denaturing high performance liquid chromatography
(dHPLC) analyses using a Transgenomics (Omaha, NE, USA)
WAVE system. Samples were run at 64.1°C. PCR products show-
ing aberrant dHPLC profiles were purified using the Multiscreen-
PCR 96-well system (Millipore, Bedford, MA, USA) followed by
direct sequencing with the appropriate forward and reversed
primers using an ABI-PRISM3100 genetic analyzer (Applied
Biosystems, Foster City, CA, USA). PCR products were sequenced
with Fw-ASXL1-Ex12 and Rev-ASXL1-Ex12. We validated this
strategy using 272 cases of AML that had been previously ana-
lyzed using PCR on genomic DNA followed by direct sequencing. 
Information on the ASXL1 mutation status of all AML cases is
available in Table 1 and of all AML cases for whom gene expres-
sion profiling has been performed (www.ncbi.nlm.nih.gov/geo, acces-
sion number GSE6891). 
The relation between ASXL1 mutations and various patients’
characteristics were determined by Student’s t-test, equal vari-
ances not assumed (continuous variables), Wilcoxon’s rank order
test (continuous variables not normally distributed) and Fisher’s
exact test (categorical variables). 
We distinguished the following cytogenetic risk categories: (I)
favorable, t(8;21), inv(16) or t(15;17); (II) unfavorable, inv(3)/t(3;3),
t(6;9), 11q23 abnormalities other than t(9;11), -5, 5q-, -7, 7q-
t(9;22) or monosomal karyotypes (MK); (III) intermediate risk,
cytogenetically normal (CN) and the remaining AML cases (CA
rest).
Overall survival (OS) end points were death (failure) and alive at
last follow up (censored), as measured from entry onto trial.
Relapse-free survival (RFS) end points were relapse, or death from
any cause, measured from the date of achievement of CR.
Distribution estimations and survival distributions of OS and RFS
were calculated by the Kaplan-Meier method and the log rank test.
Results and Discussion
ASXL1 mutations were determined in 882 cDNA sam-
ples of AMLs by RT-PCR/dHPLC followed by direct
sequencing (Table 1). ASXL1mut were identified in 46 AML
cases (5.3%): in 35 out of 775 de novo AML cases (4.5%), in
3 out of 24 post-MDS AML cases (11%), and in 4 out of
37 therapy-related AML cases (10%) (Table 2). 
All the mutations found were frame shift mutations that
caused a disruption of the PDH domain, and the most
prevalent was p.Gly646TrpfsX12 (25 of 46, 54%).
Recently, the ASXL1 p.Gly646TrpfsX12 mutation had
been suspected to represent a PCR artifact rather than a
somatic mutation.18 In the latter report, buccal samples
from AML patients with this mutation all showed the
ASXL1 mutation p.Gly646TrpfsX12. Furthermore, this
particular mutation has also been reported in approxi-
mately 25% of healthy individual samples.18 For this rea-
son, we set out to confirm the ASXL1 p.Gly646TrpfsX12
mutation in all our 25 samples, i.e. in a second independ-
ent sample of the same patient. Furthermore, in 2 available
remission samples of these AML patients, the
p.Gly646TrpfsX12 mutation in ASXL1 was absent. We
also found the mutation in the Kasumi-1 cell line with the
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Table 1. Types of ASXL1 mutations in 46 cases of acute myeloid
leukemia.
# Mutation DNA Mutation protein
2190 c.1934dupG p.Gly646TrpfsX12
2220 c.1934dupG p.Gly646TrpfsX12
2222 c.1900_1922del p.Glu635ArgfsX15
2223 c.1934dupG p.Gly646TrpfsX12
2245 c.1934dupG p.Gly646TrpfsX12
2267 c.1934dupG p.Gly646TrpfsX12
3278 c.2005_2011dup p.Ala671GlyfsX2
3315 c.1900_1922del p.Glu635ArgfsX15
3481 c.1900_1922del p.Glu635ArgfsX15
3485 c.1998_1999del p.Asp667TrpfsX3
3488 c.1934dupG p.Gly646TrpfsX12
5364 c.1900_1922del p.Glu635ArgfsX15
6452 c.1900_1922del p.Glu635ArgfsX15
6453 c.1934dupG p.Gly646TrpfsX12
6457 c.1900_1922del p.Glu635ArgfsX15
6887 c.1934dupG p.Gly646TrpfsX12
7070 c.1934dupG p.Gly646TrpfsX12
7076 c.1934dupG p.Gly646TrpfsX12
7147 c.1934dupG p.Gly646TrpfsX12
7167 c.1934dupG p.Gly646TrpfsX12
7177 c.1934dupG p.Gly646TrpfsX12
7183 c.1773C>G p.Tyr591X
7326 c.1900_1922del p.Glu635ArgfsX15
7409 c.2030_2046del p.Pro677HisfsX35
7420 c.1934dupG p.Gly646TrpfsX12
9629 c.1934dupG p.Gly646TrpfsX12
9643 c.1934dupG p.Gly646TrpfsX12
11674 c.1772dupA p.Tyr591X
13174 c.1774C>T p.Gln592X
13759 c.1934dupG p.Gly646TrpfsX12
14330 c.1933insC p.Gly645ArgfsX12
14369 c.1934dupG p.Gly646TrpfsX12
16047 c.1934dupG p.Gly646TrpfsX12
16052 c.1934dupG p.Gly646TrpfsX12
16077 c.1900_1922del p.Glu635ArgfsX15
16105 c.1934dupG p.Gly646TrpfsX12
16115 c.1900_1922del p.Glu635ArgfsX15
16143 c.1934dupG p.Gly646TrpfsX12
16157 c.1934dupG p.Gly646TrpfsX12
16161 c.1934dupG p.Gly646TrpfsX12
16168 c.1957_1964del p.Gly652ArgX2
16180 c.1934dupG p.Gly646TrpfsX12
16197 c.1934dupG p.Gly646TrpfsX12
16206 c.1934dupG p.Gly646TrpfsX12
16238 c.1945G>T p.Gly649X
16254 c.1927insA p.Gly643ArgfsX15
translocation t(8;21). In addition, we screened 91 samples
from healthy individuals, and none of them revealed a
mutation in exon 12 of ASXL1. Based on these results, we
regard the p.Gly646TrpfsX12 mutation as a real somatic
mutation. 
ASXL1mut AML were more frequent at older age
(P=0.004) and present with lower WBC count than AML
with ASXL1 wild type (ASXL1wt) (P=0.014) (Table 2).
ASXL1mut AML was associated with FAB M0 subtype
(P=0.027), but inversely related to FAB M4 subtype
(P=0.023), NPM1 mutations (P<0.0001; NPM1mut) and
FLT3ITD (P=0.014) (Table 2). 
To investigate the prognostic value of ASXL1mut, 807
patients with non-APL AML and those under 65 years of
age were considered for survival analysis. The median fol-
low up of these patients was 46.0 months (range 1.9-224
months). In this cohort, univariate survival analyses with
several known recurrent aberrations in AML demonstrat-
ed that FLT3ITD (P<0.0001, unfavorable), NPM1mut
(P=0.025, favorable), IDH2mut (P=0.02, favorable) and EVI1
overexpression (P<0.001, unfavorable) were significantly
associated with OS, whereas FLT3TKD (P=0.214), NRASmut
(P=0.53), and IDH1mut (P=0.81) were not. 
The complete response (CR) rate was significantly
reduced in patients with ASXL1mut (61% vs. 79.6%;
P=0.004). The median OS of patients with AML with or
without ASXL1mut was 15.9 months vs. 22.3 months
(P=0.019; Figure 1A). The relapse free survival was similar
between the two groups once they achieved a CR (P=0.27;
Figure 1B).
In multivariate analyses, trial-stratified and considering
other prognostic variables that were significantly associat-
ed with OS in univariate analysis, such as age, WBC, cyto-
genetics, NPM1mut, FLT3ITD, IDH2mut and EVI1 overexpres-
sion, the presence of ASXL1mut was an independent prog-
nostic factor for poor OS (HR 1.64, 95% CI= 1.12 - 2.4,
P=0.010). Recently, Chou et al.7 were unable to demon-
strate that ASXL1 mutations were an independent factor
for prognosis in AML. Apart from population differences,
this is likely due to the lower number of patient samples,
both ASXL1wild-type and mutant, in the survival analyses
and the inclusion of other covariables in the multivariate
analyses, such as RUNX1 mutations, which in fact
appeared to be associated with ASXL1 mutations.7 When
comparing both studies, it should be noted that the hazard
ratios are similar, but that the confidence interval in the
study by Chou et al.7 is greater as a result of decreased
power. It is worthy of note that Chou and co-workers indi-
cate that although ASXL1 mutations in their analysis did
not represent a significant independent factor for progno-
sis, it is highly associated with a worse survival and lower
CR rate.  
The subgroup of AML patients with intermediate-risk
cytogenetics showed a trend for worse OS for those with
ASXL1mut AML (median OS: 15.9±7.4 vs. 24.7±7.9 months;
P=0.06; Figure 1C), whereas there is no association
between OS and the ASXL1mut genotype in normal kary-
otype AML (P=0.36).  The trend for inferior OS in interme-
diate-risk cytogenetics, is significantly worse when AML
patients with FLT3wild-type (FLT3wt) and NPM1wild-type
(NPM1wt) genotypes are considered (median OS: 14.9±7.2
vs. 32.3±17.7 months; P=0.037; Figure 1D).  In the other
FLT3/NPM1 composite genotypes, the frequencies of
ASXL1mut AML are too low to allow a meaningful analysis
of the prognostic value of ASXL1mut.
The current study demonstrates that ASXL1 gene muta-
tions are common in AML. These mutations are inversely
associated with FLT3ITD, and mutually exclusive with
NPM1mut. The presence of ASXL1mut in AML is an independ-
ent poor risk factor for OS mostly due to a higher initial
resistance to chemotherapy. The adverse prognostic impact
of ASXL1mut was confirmed in the subset of patients harbor-
ing intermediate-risk cytogenetics and lacking NPM1 and
FLT3mutations, and might contribute to refine prognosis in
this subgroup of patients with uncertain outcome.
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Table 2. Distribution of ASXL1 mutations in 882 cases of acute
myeloid leukemia..
                                                ASXL1mutant              ASXL1wt             P
Total, n. (%)                                        46 (5)                     836 (95)                 
Female, n. (%)                                   19 (4)                     417 (96)                 
Male, n. (%)                                        27 (6)                     419 (94)                 
Median age at diagnosis,            54 (15-74)               47 (15-77)          0.002
years (range)
Median WBC at diagnosis,         13 (1.1-220)           23.4 (0.3-510)       0.007
¥109/L (range)
Median platelets                          66 (13-400)              61 (3-998)               
at diagnosis, ¥109/L (range)
Mean bone marrow blasts          51 (13-93)                62 (0-98)                
at diagnosis, percentage (range)
AML de novo (%)                              36 (5)                     759 (95)                 
AML post MDS (%)                           3 (11)                      24 (89)                  
AML therapy-related (%)                4 (10)                      37 (90)                  
MDS (%)                                             3 (16)                      16 (84)                  
FAB, n. (%)
M0                                                       6 (13)                      39 (87)             0.027
M1                                                       10 (6)                     158 (94)                 
M2                                                       12 (5)                     222 (95)                 
M3                                                        1 (5)                       20 (95)                  
M4                                                        2 (1)                      141 (99)            0.023
M5                                                        5 (3)                      166 (97)                 
M6                                                        1 (5)                       17 (95)                  
M7                                                          —                              1                        
RAEB                                                  3 (16)                      16 (84)                  
Unknown                                           6 (10)                      56 (90)                  
Cytogenetics,  n. (%)θ
t(8;21)                                                 4 (8)                       48 (92)                  
inv(16)                                                  —                             52                       
t(15;17)                                               1 (5)                       20 (95)                  
CA unfavorable                                 5 (4)                      113 (96)                 
MK                                                       4 (5)                       78 (95)                  
CN                                                       21 (5)                     369 (95)                 
CA rest                                               10 (7)                     136 (93)                 
Unknown                                            1 (4)                       25 (96)                  
Mutations, n. (%)
FLT3 ITD                                             4 (2)                      200 (98)            0.014
FLT3 TKD                                            2 (4)                       73 (96)                  
NPM1                                                     —                            259              <0.0001
N-RAS                                                 7 (7)                       86 (93)                  
IDH1                                                    4 (7)                       51 (93)                  
IDH2                                                    5 (5)                       91 (95)                  
EVI1                                                     6 (6)                      101 (94)                 
WBC: White blood cell count at diagnosis; FAB: French American British classification;
θKaryotypes were centrally reviewed. CA unfavorable: inv(3)/t(3;3), t(6;9), 11q23
abnormalities except t(9;11), -5, 5q-, -7, 7q- or t(9;22); MK: monosomal karyotypes; CN:
normal cytogenetics or -X or –Y as single abnormalities only; CA rest: any other abnor-
mal cytogenetics not included in any of the other categories.
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Figure 1. Kaplan-Meier survival analyses of patients with AML with or without ASXL1 mutations. (A) OS for all AML patients (<65 years). (B)
RFS for all AML patients (<65 years). (C) OS for patients with intermediate-risk AML. (D) OS for patients with intermediate-risk and FLT3wt
and NPM1wt. Survival curves in red refer to cases with ASXL1mut; those in green to ASXL1wt. The log rank P value is indicated per Kaplan-
Meier analysis.
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